Variable access to clopidogrel in a harmonized EU market.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Value in Health

• Publication date

  2008-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1524-4733.2008.00331.xPMID 18489520
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention—summary article: A report of the American college of cardiology/American heart association task force on practice guidelines(ACC/AHA/SCAI writing committee to update the 2001 guidelines for percutaneous coronary intervention)

  2006cited by this paper
• Off-label prescribing among office-based physicians.

  2006cited by this paper
• ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention

  2006cited by this paper
• ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention

  2006cited by this paper
• The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina

  2005cited by this paper
• The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina.

  2005cited by this paper
• ESC guidelines for percutaneous coronary interventions.

  2005cited by this paper
• Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

  2005cited by this paper
• Herceptin and early breast cancer: a moment for caution.

  2005cited by this paper
• Variations and increase in use of statins across Europe: data from administrative databases

  2004cited by this paper
• Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.

  2004cited by this paper
• The drug budget silo mentality in Europe: an overview.

  2003cited by this paper
• High persistence of statin use in a Danish population: compliance study 1993-1998.

  2002cited by this paper
• Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

  2001cited by this paper
• Conducting pharmacoepidemiologic research in Denmark

  2001cited by this paper
• Assessment of biotechnology drugs: what are the issues?

  1999cited by this paper

• A systematic review of patch angioplasty versus primary closure for carotid endarterectomy.

  2019cites this paper
• The Atlantic divide in coronary heart disease: Epidemiology and patient care in the US and Portugal.

  2017cites this paper
• Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.

  2013cites this paper
• Cross-country variation in medicines use; a pharmaceutical system perspective

  2013influential citation
• SHOULD THE DECISION-MAKING PROCESS OF REIMBURSING MEDICINES BE IMPROVED?

  2012cites this paper
• A 10-Year Analysis of the Effects of Media Coverage of Regulatory Warnings on Antidepressant Use in The Netherlands and UK

  2012cites this paper
• Uusien lääkkeiden markkinoille tulo ja lääkekustannuksiin vaikuttaminen

  2012cites this paper
• Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries.

  2012cites this paper
• Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study

  2011cites this paper
• New chemical entities and their market penetration in Finland during the years 1996 through 2005.

  2009cites this paper